News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search


PHARMAC’s claims of success misleading

14 May 2004

News Release

PHARMAC’s claims of asthma campaign success misleading DTC advertising catalyst for biggest dose reductions

Auckland May 14, 2003

New Zealand’s biggest supplier of asthma medications, GlaxoSmithKline is intrigued PHARMAC has come on board to help reduce doses of inhaled corticosteroid used in asthma. PHARMAC’s move comes after the biggest recent dose reduction, which was stimulated by Direct-To-Consumer Advertising (DTCA) of asthma medicines and the pro-active actions of GPs and patients.

GlaxoSmithKline Medical Director Dr Ian Griffiths says DTCA has been the single biggest catalyst for the positive changes despite opposition by PHARMAC to this informational tool. “Any reduction in average dose of inhaled corticosteroid should be attributed to good medical practice, patient motivation, responsible advertising and increased use of other therapies.

“GSK believes a contributing factor to historical high dosing was a PHARMAC funding policy forcing many patients to use doses in excess of manufacturer recommendations before being allowed to access other therapies. We are delighted to see PHARMAC are accepting responsibility for this problem.

“The biggest and most dramatic reduction in average inhaled corticosteroid dose came when GSK advertised the discontinuation of its beclomethasone inhalers and suggested patients consult their doctor about alternatives. This motivated patients to see their doctors and sparked the sharpest decline in dosing seen in recent years as doctors proactively addressed high dosing problems.

“GSK believes PHARMAC’s limited budget could be more effectively used to fund more medicines and reduce funding restrictions rather than developing costly campaigns to influence doctors’ prescribing behaviour,” says Dr Griffiths.


© Scoop Media

Culture Headlines | Health Headlines | Education Headlines

Legendary Bassist David Friesen Plays Wellington’s Newest Jazz Venue

Friesen is touring New Zealand to promote his latest album Another Time, Another Place, recorded live at Auckland's Creative Jazz Club in 2015. More>>

Howard Davis Review: The Father - Descending Into The Depths of Dementia

Florian Zeller's dazzling drama The Father explores the effects of a deeply unsettling illness that affects 62,000 Kiwis, a number expected to grow to 102,000 by 2030. More>>

Howard Davis Review: Blade Runner Redivivus

When Ridley Scott's innovative, neo-noir, sci-fi flick Blade Runner was originally released in 1982, at a cost of over $45 million, it was a commercial bomb. More>>

14-21 October: New Zealand Improv Festival In Wellington

Imagined curses, Shibuya’s traffic, the apocalypse, and motherhood have little in common, but all these and more serve as inspiration for the eclectic improvised offerings coming to BATS Theatre this October for the annual New Zealand Improv Festival. More>>


Bird Of The Year Off To A Flying Start

The competition asks New Zealanders to vote for their favourite bird in the hopes of raising awareness of the threats they face. More>>

Scoop Review Of Books:
Jenny Abrahamson's John & Charles Enys: Castle Hill Runholders, 1864-1891

This volume will be of interest to a range of readers interested in the South Island high country, New Zealand’s natural environment, and the history of science. More>>